US5472985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1994-09-02
•
Granted: 1995-12-05
•
Expires: 2014-09-02
Abstract
Abstract TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
Inventors
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 03:45
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/395; A61K31/40; A61P; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10; A61P9/12; A61P9/14; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; C07K16/00; C07K16/18; C07K16/22; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/74; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/321; G01N2800/323
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
79 words
A method for inhibiting pathological proliferation of mammalian smooth muscle cells which method comprises administering to a mammal at risk of a condition characterized by pathological proliferation of smooth muscle cells, the following: an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine, or a structural analog thereof effective to activate or stimulate production of TGF-beta, wherein the amount is administered over time to the mammal as a preventative measure, for a condition selected from the group consisting of atherosclerosis, thrombosis, myocardial infarction, and stroke.
Claim 2
Independent Claim
79 words
A method for inhibiting pathological proliferation of mammalian smooth muscle cells which method comprises administering to a mammal at risk of a condition characterized by pathological proliferation of smooth muscle cells, the following: an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine, or a structural analog thereof effective to activate or stimulate production of TGF-beta, wherein the amount is administered over time to the mammal as a preventative measure, for a condition selected from the group consisting of atherosclerosis, thrombosis, myocardial infarction, and stroke.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein the administration is conducted once or twice daily.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein the TGF-beta activator or production stimulator is administered orally.
Claim 5
Dependent Claim
91 words
A therapeutic method for inhibiting pathological proliferation of vascular smooth muscle cells associated with a condition selected from the group consisting of atherosclerosis, thrombosis, myocardial infarction and stroke, comprising administering to a mammal afflicted with said condition, an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or a structural analog thereof effective to activate or stimulate production of TGF-beta, wherein the TGF-beta activator or production stimulator acts on vascular smooth muscle cells to inhibit the pathological proliferation of said smooth muscle cells, while not significantly reducing the proportion of cells completing the cell cycle and dividing.
Claim 6
Dependent Claim
91 words
A therapeutic method for inhibiting pathological proliferation of vascular smooth muscle cells associated with a condition selected from the group consisting of atherosclerosis, thrombosis, myocardial infarction and stroke, comprising administering to a mammal afflicted with said condition, an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or a structural analog thereof effective to activate or stimulate production of TGF-beta, wherein the TGF-beta activator or production stimulator acts on vascular smooth muscle cells to inhibit the pathological proliferation of said smooth muscle cells, while not significantly reducing the proportion of cells completing the cell cycle and dividing.
Claim 7
Dependent Claim
15 words
The method of claim 4 wherein the TGF-beta activator or production stimulator is administered orally.
Claim 8
Dependent Claim
10 words
The method of claim 4 wherein the condition is atherosclerosis.
Claim 9
Dependent Claim
22 words
The method of claim 6 wherein the TGF-beta activator or production stimulator is administered locally to an arterial lesion associated with atherosclerosis.
Claim 10
Dependent Claim
10 words
The method of claim 4 wherein the administration is systemic.
Claim 11
Dependent Claim
10 words
The method of claim 1 wherein the condition is atherosclerosis.
Claim 12
Dependent Claim
15 words
The method of claim 1 wherein the mount is administered in a series of doses.
Claim 13
Dependent Claim
51 words
A therapeutic method for inhibiting pathological proliferation of vascular smooth muscle cells associated with atherosclerosis, comprising systemically administering to a mammal afflicted with atherosclerosis, an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or a structural analog thereof effective to elevate the level of active TGF-beta, to inhibit the pathological proliferation of said smooth muscle cells.
Claim 14
Dependent Claim
51 words
A therapeutic method for inhibiting pathological proliferation of vascular smooth muscle cells associated with atherosclerosis, comprising systemically administering to a mammal afflicted with atherosclerosis, an amount of trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine or a structural analog thereof effective to elevate the level of active TGF-beta, to inhibit the pathological proliferation of said smooth muscle cells.
Claim 15
Dependent Claim
12 words
The method of claim 1, 4 or 11 wherein trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-ethylamine is administered.
References Cited (Backward Citations)
US4235988A
Cited
US5098903A
Cited
US4442119A
Cited
US5047431A
Cited
US5015666A
Cited
US4879315A
Cited
WO1985000107A1
Cited
US4826672A
Cited
US4859585A
Cited
US4962091A
Cited
EP0260066B1
Cited
US4839155A
Cited
US5120535A
Cited
US4997652A
Cited
EP0374044A2
Cited
US5112305A
Cited
US5242397A
Cited
US4990538A
Cited
WO1991015222A2
Cited
US5189046A
Cited
US5192525A
Cited
WO1992008480A1
Cited
US5171217A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-12-04 | 1999-06-05 | 1999-12-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-12-04 | 2003-06-05 | 2003-12-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-12-04 | 2007-06-05 | 2007-12-05 | $7700.00 | Window Closed / Lapsed |